Eisai, Purdue's insomnia candidate improves postural stability in Phase I

Eisai Co. Ltd. (Tokyo:4523) and Purdue Pharma L.P. (Stamford, Conn.) reported top-line data from the Phase I Study 108 showing that both doses of insomnia candidate lemborexant (E2006) given each night at

Read the full 320 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE